Overview Evaluating the Pharmacokinetics and Pharmacodynamics of Romiplostim in Patients With Immune Thrombocytopenia (ITP) Status: Completed Trial end date: 2017-08-01 Target enrollment: Participant gender: Summary The objective of evaluating the pharmacokinetics and pharmacodynamics of romiplostim in patients with immune thrombocytopenia. Phase: Phase 1/Phase 2 Details Lead Sponsor: Kyowa Hakko Kirin China Pharmaceutical Co., LTD.Kyowa Hakko Kirin China Pharmaceutical Co.,LTD.